Emicizumab Associated Rhabdomyolysis in Hemophilia A
- https://doi.org/10.2991/chi.k.200924.001How to use a DOI?
- Emicizumab, rhabdomyolysis, hemophilia A
Emicizumab is increasingly the front-line treatment for patients with Hemophilia A with or without inhibitors. Rhabdomyolysis is a syndrome of muscle necrosis and release of intracellular muscle constituents into the circulation. Creatine kinase (CK) levels are typically markedly elevated, and muscle pain and myoglobinuria may be present. The severity of illness ranges from asymptomatic elevations in serum muscle enzymes to life-threatening disease associated with extreme enzyme elevations, electrolyte imbalances, acute kidney injury and disseminated intravascular coagulation. We present a case of an African American male with severe hemophilia A and history of factor VIII inhibitor, maintained on emicizumab prophylaxis, who developed rhabdomyolysis with a symptomatic hyperCKemia. To date, there is no known link between rhabdomyolysis to emicizumab. This report brings to light the possibility of symptomatic rhabdomyolysis as a potential side effect of emicizumab after moderate exertional activity.
- © 2020 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
- Open Access
- This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
Cite this article
TY - JOUR AU - Joseph A. Wilson AU - Stephanie Hayden AU - Alexander Asamoah AU - Vivek R. Sharma AU - David C. Jennings AU - Ashok B. Raj PY - 2020 DA - 2020/10 TI - Emicizumab Associated Rhabdomyolysis in Hemophilia A JO - Clinical Hematology International SP - 165 EP - 167 VL - 2 IS - 4 SN - 2590-0048 UR - https://doi.org/10.2991/chi.k.200924.001 DO - https://doi.org/10.2991/chi.k.200924.001 ID - Wilson2020 ER -